HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New Elite Feature: Chart Templates — Your indicators and design everywhere on Finviz

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Annovis Bio Inc.

Contributing Author

Recent Articles by Annovis Bio Inc.

Apr-02
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections ANVS +7.55% GlobeNewswire
Mar-31
Annovis Publishes Historical Review of Buntanetap in The Scientist ANVS +10.95% GlobeNewswire
Mar-19
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study ANVS +8.10% GlobeNewswire
Mar-16
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results ANVS +12.30% GlobeNewswire
Mar-03
Annovis Announces Two Presentations at the AD/PD 2026 International Conference ANVS GlobeNewswire
Feb-12
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease ANVS GlobeNewswire
Dec-18
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients ANVS GlobeNewswire
Dec-16
Annovis to Host Corporate Update Webinar on January 28, 2026 ANVS GlobeNewswire
Dec-03
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group ANVS +5.44% GlobeNewswire
Nov-24
Annovis Announces Two Presentations at the CTAD 2025 Conference ANVS +7.92% GlobeNewswire
Nov-18
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study ANVS +11.22% GlobeNewswire
Nov-17
Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients ANVS +29.49% GlobeNewswire
Nov-12
Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results ANVS +15.17% GlobeNewswire
Nov-06
Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer's Program ANVS GlobeNewswire
Oct-27
Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules ANVS GlobeNewswire
Oct-15
Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock ANVS +12.15% ANVS +7.74% GlobeNewswire
Oct-10
Annovis Announces $6 Million Registered Direct Offering of Common Stock ANVS -22.73% GlobeNewswire
Oct-09
Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment ANVS GlobeNewswire
Sep-25
Annovis Appoints Mark Guerin as Chief Financial Officer ANVS GlobeNewswire
Sep-16
Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap ANVS GlobeNewswire
Sep-02
Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference ANVS GlobeNewswire
Aug-12
Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results ANVS GlobeNewswire
Aug-07
Annovis Completes Full Patent Transfer to Crystal Buntanetap ANVS GlobeNewswire
Jun-26
Annovis to Attend the AAIC 2025 with Four Poster Presentations ANVS -5.24% GlobeNewswire
Jun-19
Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance ANVS GlobeNewswire
Jun-05
Annovis to Host Webinar and Live Q&A on June 24, 2025 ANVS -5.86% GlobeNewswire
May-13
Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results ANVS +9.68% GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)